{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"622.81","value":"1297.65"},{"groupId":"OG001","spread":"676.45","value":"2196.65"},{"groupId":"OG002","spread":"1392.74","value":"3995.68"},{"groupId":"OG003","spread":"1713.17","value":"2668.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Peak Plasma Concentration (Cmax) of RP6530","dispersionType":"Standard Deviation","groups":[{"description":"RP6530 administered 200 mg orally twice a day.","id":"OG000","title":"Dose escalation_Cohort 1_200 mg"},{"description":"RP6530 administered 400 mg orally twice a day.","id":"OG001","title":"Dose escalation_Cohort 2_400 mg"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"OG002","title":"Dose escalation_Cohort 3_800 mg (Fasting)"},{"description":"RP6530 administered 800 mg orally twice a day under fed condition","id":"OG003","title":"Dose escalation_Cohort 4_800 mg (Fed)"}],"paramType":"MEAN","populationDescription":"Peak Plasma Concentration (Cmax) of RP6530 at Cycle 1 day 1","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1","title":"Peak Plasma Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}